TNF inhibitors, specifically infliximab or adalimumab, had been used previously in 10.8% (4/37) of patients for conditions other than PG: Crohn's disease (infliximab, n = 2) and ulcerative colitis (infliximab, n = 1; adalimumab, n = 1). The gene discussed is TNF; the disease is Crohn disease.